Short answer
Thermo Fisher Scientific (TMO) filed its Q2 2026 10-Q quarterly report on Jul 31, 2026 for the quarter ended Jun 27, 2026. Quarterly revenue was $12.0B (up 10.5% year over year) with net income of $1.7B.
Q2 2026 key financials · XBRL
- Revenue
- $12.0B
- +10.5% YoY · +9.0% QoQ
- Net income
- $1.7B
- +7.4% YoY · +5.1% QoQ
- Operating margin
- 17.4%
- EPS (diluted)
- $4.67
- +9.1% YoY · +5.4% QoQ
Source: XBRL data from the Thermo Fisher Scientific (TMO) Q2 2026 10-Q on SEC EDGAR. USD.
Thermo Fisher Scientific Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $11,994M, up 10% YoY from $10,855M; organic growth 5%
- GAAP operating margin 17.4% vs 16.9% YoY; adjusted margin 22.8% vs 21.9%
- Best segment Laboratory Products and Biopharma Services: revenue $6,693M, up 12%; worst Analytical Instruments: $1,847M, up 7%
- Cash $4,064M vs $9,852M at year-end; debt $42,549M vs $39,384M
- Six-month operating cash flow $3,317M vs $2,122M; acquisitions used $8.87B, buybacks $4.00B, dividends $0.34B
- Outlook: 2026 GAAP tax rate 9%-11%, adjusted tax rate approximately 11.5%, capital expenditures $1.9B-$2.1B
Risk Factors
- No material risk-factor changes; quarterly filing refers investors to the December 31, 2025 Form 10-K
- Capital-allocation risk; $1.0 billion remained available under the $5.00 billion repurchase authorization
- Insider-trading compliance risk; CEO modified a Rule 10b5-1 plan covering 108,888 shares
- Insider-trading compliance risk; COO adopted a Rule 10b5-1 plan covering 12,400 shares
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Thermo Fisher Scientific quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.